Paola Queirolo
Milan, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 207 publications
Real-World Data on Characteristics and Management of Patients with Actinic Keratosis: A Cancer Center Experience.
Journal: Medical sciences (Basel, Switzerland)
Published: July 13, 2026
A phase 2 study of abemaciclib in patients with brain metastases secondary to non-small cell lung cancer or melanoma.
Journal: Neuro-oncology advances
Published: December 19, 2025
Nivolumab for Resected Stage III or IV Melanoma at 9 Years.
Journal: The New England journal of medicine
Published: October 22, 2025
High BRAF variant allele frequency predicts poor outcomes in metastatic melanoma patients treated with BRAF/MEK inhibitors.
Journal: Journal of translational medicine
Published: October 02, 2025
Cemiplimab in cutaneous squamous cell carcinoma: a longer follow-up study focusing on the late toxicities.
Journal: Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
Published: September 21, 2025
Age-specific melanoma risk associated with melanocytic nevi: a pooled analysis from the M-SKIP project.
Journal: Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
Published: July 31, 2025
Sex and gender influence on adverse events for melanoma patients: a comprehensive review and meta-analysis.
Journal: British journal of cancer
Published: June 17, 2025
Evaluation of Sonidegib Cytoreductive Activity in Locally Advanced Basal Cell Carcinoma Treatment: A Delphi Consensus.
Journal: International journal of dermatology
Published: June 04, 2025
Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma.
Journal: The New England journal of medicine
Published: June 02, 2025
Combined immunotherapy with nivolumab and ipilimumab with and without sequential or concomitant stereotactic radiotherapy in patients with melanoma brain metastasis: An international retrospective study.
Journal: European journal of cancer (Oxford, England : 1990)
Published: April 08, 2025
Randomized, double-blind, phase III LEAP-003 study of first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab for unresectable or metastatic melanoma.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: February 27, 2025
Last Updated: 09/26/2026